No Direct Pharmacokinetic Interaction Between Leflunomide and Terbinafine, But Additive Hepatotoxicity Risk Requires Monitoring
Based on the available evidence, there is no documented direct drug-drug interaction between leflunomide and terbinafine, but their concurrent use requires careful hepatic monitoring due to the independent hepatotoxic potential of both medications 1, 2, 3, 4.
Mechanism Analysis
Leflunomide Metabolism and Interactions
- Leflunomide is metabolized to its active metabolite M1 (teriflunomide) and undergoes biliary recycling 4
- The documented drug interactions for leflunomide are limited: rifampin increases leflunomide levels, and coadministration with methotrexate increases hepatotoxicity risk without pharmacokinetic interaction 1, 5
- Leflunomide inhibits CYP2C9 in vitro but has minimal documented interactions with other CYP450 substrates 4
Terbinafine Metabolism and Interactions
- Terbinafine has minimal drug-drug interactions and is primarily an inhibitor of CYP2D6 2, 3
- The only potentially significant interactions are with drugs metabolized by CYP2D6 (e.g., tricyclic antidepressants, certain beta-blockers) 2, 3
- Terbinafine does not interact with the metabolic pathways relevant to leflunomide 3, 6, 7
Primary Clinical Concern: Additive Hepatotoxicity
The main risk when combining these medications is additive hepatotoxicity, not a pharmacokinetic interaction:
Leflunomide Hepatotoxicity Profile
- Can cause severe liver injury, including fatal outcomes 1, 5
- Most cases occur within 6 months of therapy in patients with multiple risk factors 1, 8
- Requires monthly CBC and liver function tests (LFTs) for first 6 months, then every 6-8 weeks 1
Terbinafine Hepatotoxicity Profile
- Associated with minimal hepatic toxicity, but rare serious hepatotoxicity reported 2
- Not recommended in patients with active or chronic liver disease 2
- Baseline LFTs recommended in patients with heavy alcohol use, hepatitis, or hematological abnormalities 2
Clinical Management Algorithm
If concurrent use is necessary:
Baseline Assessment
- Obtain comprehensive LFTs (AST, ALT, alkaline phosphatase, bilirubin)
- Complete blood count with differential
- Document any history of liver disease, alcohol use, or hepatitis
Monitoring Schedule
Discontinuation Criteria
- Discontinue both medications if liver enzymes exceed 3× upper limit of normal 1
- Stop immediately if clinical signs of hepatotoxicity develop (jaundice, dark urine, right upper quadrant pain, unexplained fatigue)
Risk Mitigation
- Avoid in patients with pre-existing liver disease
- Counsel patients to avoid alcohol during treatment
- Educate about hepatotoxicity warning signs
Common Pitfalls to Avoid
- Do not assume terbinafine's "minimal drug interactions" profile 2, 7 means it's safe to combine with all hepatotoxic drugs without enhanced monitoring
- Do not rely on standard monitoring intervals for either drug alone—the combination requires the more intensive leflunomide monitoring schedule
- Do not overlook that leflunomide's long half-life (>1 week for M1) means hepatotoxicity risk persists even after discontinuation 4
Alternative Considerations
If hepatotoxicity risk is unacceptable:
- Consider topical antifungals for limited onychomycosis (amorolfine, ciclopirox) 2
- Delay terbinafine treatment until leflunomide can be discontinued with appropriate washout
- Use cholestyramine or activated charcoal to accelerate leflunomide elimination if urgent antifungal therapy needed 4
The evidence strongly supports that terbinafine has one of the most favorable drug interaction profiles among oral antifungals 6, 7, making it preferable to azoles (itraconazole, fluconazole) which have extensive CYP3A4 interactions. However, this does not eliminate the need for vigilant hepatic monitoring when combined with leflunomide.